GSK’s Darapladib Poised To Become Latest Cardiovascular Outcomes Casualty
This article was originally published in The Pink Sheet Daily
Executive Summary
Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.